AstraZeneca and HutchMed have claimed their first approval – in China – for cMET inhibitor savolitinib as a treatment of patients with a form of non-small cell lung cancer.

TAIPEI, Feb 3 (Reuters) - Taiwan and China need to talk to each other to achieve peace given the "multifold changes" in the international situation, Taiwan's President Lai Ching-te said on Monday ...

which have exploited the exemption to ship individual consumer goods packages directly from China to avoid previous U.S. tariffs on Chinese imports. Such small shipments often are not screened at ...

Lung cancer combination advances in China In other news today ... AstraZeneca's EGFR inhibitor Tagrisso (osimertinib) in non-small cell lung cancer (NSCLC) patients with MET amplification after ...

From Woody’s column archives, April of 2018, the feelings relevant anew following the devastating wildfires in Southern ...

What’s the best way to remember where we’ve been?

You might be surprised at how transformative this small change can be for your kitchen that is a hub of activity in your home. After all, it's hard not to imagine all the tangled mess that comes with ...